Lloyd Czaplewski created the Abgentis “fast-follower” concept: to fix the liabilities of a compound that was effective in the market but was not competitive due to resistance and side-effects.
Abgentis will deploy Lloyd's unique insight into the structure-activity relationships, microbiology, pharmacology and efficacy of antibacterial DNA supercoiling inhibitors to rapidly re-engineer and optimise, to improve the potency and resistance frequency and to minimise the side-effects to create an internationally competitive product.
Abgentis has clear evidence that a low-risk path to a novel and effective new broad-spectrum antibacterial has been identified and that the objectives of improved
potency, reduced resistance and a reduction in side-effects can be achieved.
Abgentis will focus on identifying a potential clinical candidate with compelling in vivo efficacy in models of infection to create a high value preclinical asset.